Blueprint Medicines Corporation BPMC reported a loss of $2.20 per share for the third quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of $2.39. The company had incurred a loss of ...

Focus on winnable opportunities. Use tools to refine what is and isn’t a winnable deal. Create a plan with your prospect. Manage yourself for success. Contrary to what you see in pop culture, sales is ...

Stomach cancer may be a bust for Blueprint Medicines’ Ayvakit, but now the kinase inhibitor is nearing a potential FDA label expansion in a rare blood disorder. The company hopes this use can catapult ...

CHICAGO, April 27, 2026 /PRNewswire/ -- Blueprint is pleased to announce the successful sale of Parkdale Center, a behavioral healthcare business specializing in partial hospitalization (PHP), ...